The anti-cancer effects of phenformin in thyroid cancer cell lines and in normal thyrocytes.

The anti-cancer effects of phenformin in thyroid cancer cell lines and in normal thyrocytes. Oncotarget. 2019 Nov 05;10(60):6432-6443 Authors: Coperchini F, Croce L, Denegri M, Awwad O, Ngnitejeu ST, Magri F, Chiovato L, Rotondi M Abstract Phenformin is a biguanide drug which, besides the original anti-diabetic effect, also exerts anti-cancer effects. The aim of this study was to further characterize these latter in terms of both cell-viability and modulation of the secretion of the pro-tumorigenic chemokine CXCL8. Normal human thyrocytes in primary cultures (NHT) and thyroid cancer cell lines, TPC-1 and 8505C (RET/PTC and BRAFV600E mutated, respectively) were treated with increasing concentrations of phenformin at different times. Cell-viability was assessed by WST-1 and further characterized by AnnexinV/PI staining and cell proliferation colony-assay. CXCL8 levels were measured in cell supernatants. Phenformin reduced cell-viability in TPC-1 and 8505C and their ability to form colonies. In NHT cells, phenformin affected cell-viability only at the maximal dose but interestingly it inhibited CXCL8 secretion at all the concentrations not affecting cell-viability. Phenformin had no effect on CXCL8 secretion in thyroid cancer cell lines. Thus, phenformin exerts anti-cancer effects on both cancer cells (cell death induction) and surrounding normal cells (inhibition of CXCL8 secretion). These results highlight that the anti-cancer effects...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research